Autonomix Medical, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Autonomix Medical amended and restated its 2023 Stock Plan effective October 29, 2026, adding 750,000 shares to the plan reserve (total now 750,353 shares available). The plan includes a 5% annual evergreen increase in shares on April 1st each year through 2033. Annual individual limits cap stock options/SARs and stock awards/units at $1M fair value per employee; directors capped at $500K. Plan terminates June 28, 2033.
Why this rating
750K new shares = ~12% of company's ~$6.3M market cap; material dilution headwind but standard equity-grant practice for retention. Evergreen mechanism adds recurring dilution risk. Neither transformational nor routine given company scale.
Price action (we called it neutral)
before filing · preread $1.66 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.